Human trials set to begin on Ebola vaccine - Technical.ly Baltimore

Sciences

Jan. 19, 2016 12:23 pm

Human trials set to begin on Ebola vaccine

It's a new phase for East Baltimore's Profectus Biosciences and its quest to develop a vaccine.

Ebola virus budding from the surface of a Vero cell.

(Photo via Wikimedia Commons)

Whether it’s making headlines or not, the quest to discover an Ebola vaccine continues for biotech companies, including Profectus Biosciences.

The Ebola outbreak was back in the news recently as a new case was reported in Sierra Leone only one day after the outbreak was declared over.

The East Baltimore company, which received new funding for its vaccine candidate as the recent Ebola outbreak was raging in West Africa, is set to begin clinical trials on humans, the company announced on Tuesday.

Workers at an Ebola quarantine in eastern Sierra Leone. Aug. 2, 2014.

Workers at an Ebola quarantine in eastern Sierra Leone. Aug. 2, 2014. (Photo by Flickr user European Commission DG ECHO, used under a Creative Commons license)

Profectus is developing vaccines to prevent against three viruses that cause hemorrhagic fevers, known as filoviruses. The antidote is specifically engineered to protect against the Ebola strain that killed more than 28,000 people primarily in Liberia, Sierra Leone and Guinea.

The company’s Phase 1 clinical trials will include testing on 39 people. As part of the study, the participants will be separated into three groups, and given progressively higher doses of the vaccine. It’s the same dosage that the company said was successful on preclinical trials in monkeys.

In mid-2017, the company expects to begin trials on the vaccine that protects against all filoviruses, including multiple strains of Ebola and Marburg virus.

The company is also developing a freeze-dried version of the vaccine that allows use without refrigerated storage.

A 26-year-old man receives a dose of an investigational Ebola vaccine at the NIH Clinical Center in Bethesda, Md.

A 26-year-old man receives a dose of an investigational Ebola vaccine at the NIH Clinical Center in Bethesda, Md. (Photo by Flickr user NIAID, used under a Creative Commons license)

After years of “treading water,” Profectus received money for the study from a consortium including the U.S. Department of Defense’s Medical Countermeasures Systems-Joint Vaccine Acquisition Program (MCS-JVAP) both directly and through contracts with Battelle, the Biomedical Advanced Research and Development Authority (BARDA) and the National Institutes of Health (NIH).

Advertisement

In mid-2017, the company expects to begin trials on the vaccine that protects against all filoviruses, including multiple strains of Ebola and Marburg virus. The company is also developing a freeze-dried version of the vaccine that allows use without refrigerated storage.

Separately, the company is working on an HIV candidate vaccine with the University of Maryland-Baltimore’s Institute of Human Virology that also recently entered human trials.

You must appreciate accurate, relevant and productive community journalism.  Support this sort of work from professional reporters with seasoned editors.  Become a Technical.ly member for $12 per month -30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

Columbia-based Osiris Therapeutics to be acquired in $660M deal

Partnering with French firm, Early Charm Ventures looks to European market

Gliknik receives $15M payment from Pfizer after reaching clinical milestone

SPONSORED

Baltimore

At 14 West, only go-getters need apply

Baltimore, MD

SmartLogic

Product Designer

Apply Now
Baltimore, MD 21201

Agora Financial

Jr. Project Manager / Business Analyst

Apply Now
Baltimore, MD

SmartLogic

Developer

Apply Now

JHU spinout WindMIL Therapeutics expands to Philly, adds two new executives

Baltimore biotech company partners with JuiceBot on food safety

JHU startup PathoVax raises $2.75M, grows team

SPONSORED

Baltimore

Learn to lead digital transformation at Phorum 2019

Baltimore

Mindgrub

Automation Engineer

Apply Now
1629 Thames Street Suite 400 Baltimore, MD 21231

Contrast Security

Software Engineer Java

Apply Now
1629 Thames Street, Suite 400 Baltimore, MD 21231

Contrast Security

Software Engineer Ruby

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!